GlycoConnect® technology enables precise, site‑specific conjugation by modifying the antibody’s native glycan rather than engineering the antibody sequence. This approach supports fast, stable generation of ADCs while preserving antibody structure and delivering highly consistent drug attachment.
Chemoenzymatic Conjugation of Toxic Payloads
Enzymatic strategies for clinical development of ADCs
Readily Accessible Bicyclononynes for Bioorthogonal Labeling
HydraSpace® technology is a hydrophilic spacer technology that improves ADC solubility and stability, enhancing the therapeutic index. When combined with GlycoConnect® technology, it supports better tolerability and more predictable pharmacokinetics compared with conventional ADC architectures.
The toxSYN® linker‑payload platform provides one of the broadest portfolios of clinically validated cytotoxic mechanisms available, enabling precise alignment of ADC mode‑of‑action with the specific biology of each tumor.
From rapidly proliferating cells to quiescent cancer stem cell populations, our diverse payload classes allow developers to select the optimal mechanism to drive maximal therapeutic effect. By integrating seamlessly with our conjugation and polar spacer technologies, toxSYN® platform empowers partners to design best‑in‑class ADCs with a level of biological fit and efficacy potential that platforms with a narrower payload offering simply cannot match.
Choose from the following linker-payloads, attach to your antibody under a technology evaluation and go straight into ADC product development following positive POC.
| Linker-Payload | Mode-of-Action | Chemical structure derivative |
|---|---|---|
| 1. SYNtecan E™* | Topoisomerase 1 inhibitor | Camptothecin |
| 2. SYNeamicin D™* | DNA damaging agent | Calicheamicin |
| 3. SYNeamicin G™* | ||
| 4. SYN-PNU™* | Nemorubicin | |
| 5. SYN-PBD™* | Pyrrolobenzodiazepine | |
| 6. SYNstatin E™ | Microtubule inhibitor | Auristatin |
| 7. SYN-duo® CA | Dual-payload TOP1i + MTi | Camptothecin + Auristatin |
* Patent protection filed beyond the claims of GlycoConnect® technology and HydraSpace® polar spacer
Lonza’s ADC technology platforms offer developers a streamlined path to differentiated ADCs without the need for antibody engineering. Our ADC technology delivers stable, homogeneous conjugates with enhanced efficacy and reduced off‑target toxicity, enabling a wider therapeutic window and more predictable performance. Its consolidated suite of conjugation and payload technologies allows any antibody to be transformed into a high‑performing ADC in just days, accelerating discovery and shortening time to clinic.
Our licensing model is built around one simple premise: all you need to bring is an antibody.
Everything else—our GlycoConnect® conjugation technology, HydraSpace® polar spacer, the full toxSYN® linker‑payload portfolio, and all required platform components—is delivered under a single, unified license. Partners also benefit from Lonza’s fully integrated global GMP supply chain, ensuring secure availability of every component from research grade to GMP grade for clinical and commercial supply. This enables ADCs initiated in Oss discovery labs to transition seamlessly into Lonza’s GMP network, accelerating development with minimal tech‑transfer burden.
